Therapeutics: Nuclear receptor subfamily 0 group B member 2 (NR0B2); NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1)

In vitro and mouse studies suggest promoting NR0B2 activity could help treat NLRP3 inflammasome-driven gout and kidney damage. In in vitro assays, NRB02 bound to NLRP3 to negatively regulate its activ...